Page 24 - Epic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Exact Sciences Announces Preliminary Fourth Quarter 2020 Results - Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M News provided by Share this article Share this article MADISON, Wis., Jan. 10, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020. "I'm incredibly proud of how the Exact Sciences team came together during 2020 to ...

4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Genetron Health Targeting Early Cancer Detection Pan-European Initiative to Build Tools for Sharing Genomic Data UK Government Unveils New Genomic Healthcare Strategy Foundation Medicine Liquid Biopsy Gets FDA Approval American Heart Association Develops Genetic Testing Guidelines Yourgene Health Gets CE Mark for Iona NIPT Test NorthShore Looks to Expand Genomics Integration Into Primary Care Germline Results From Tumor-Normal Sequencing Guides Precisi...

World Whole Genome and Exome Sequencing Markets, 2021-2025: COVID-19 Drives Overnight Global Growth in Pathogen Sequencing - A New Industry Emerges. December 16, 2020 10:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com's offering. The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the wor...

World Human Gene Sequencing Markets, Strategies & Trends Report 2021-2025: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities December 15, 2020 04:53 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com's offering. Will all newborns receive genetic testing at birth? Is COVID-19 holding the industry back? Where are the over 800 locations that have high throughput sequencing devices? The plummeting costs for Genome Sequencing is creating a g...

New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice - Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease - New meta-analysis of data from more than 10,000 patients with node-negative disease, including the results of TAILORx, supports the Oncotype DX Breast Recurrence Score® test as the standard of care genomic test in early-stage, invasive breast cancer News...